Resources

Discovery Park, Kent’s science and innovation hub, has launched the seventh edition of its Discovery Spark accelerator programme, welcoming 12 startups to its campus in Sandwich.

Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease.

Engitix announced a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets driving liver fibrosis regression.

New strategic collaboration aims to overcome long‑standing barriers in brain‑targeted drug discovery

PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO).

Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE

New conversational AI platform leverages the world's largest human genetics database to power target discovery and validation.

IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53 million.

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in children

Poolbeg announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)

Firefinch Software sets out what instrument manufacturers need to know about building software that meets Good Manufacturing Practice (GMP) standards

King’s College London has spun out Korecyte Bio Ltd (Korecyte) and Cell and Gene Therapy Catapult (CGT Catapult) has enabled the spinout.

Collaborative Drug Discovery (CDD) announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.

Coulter Partners successfully led a search for Neumirna Therapeutics and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer.

Microbiotica announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.

Poolbeg will present data on POLB 001 at the European Hematology Association Congress (EHA), taking place 11-14 June 2026 in Stockholm, Sweden.

Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).